2 options
Nonpharmacologic treatments for menopause-associated vasomotor symptoms / prepared for Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service ; prepared by, Evidence-based Synthesis Program (ESP) Center, Durham VA Healthcare System ; principal investigators, Karen M. Goldstein, Remy R. Coeytaux, John W. Williams ; co-investigators, Megan Shepherd-Banigan, Adam P. Goode, Jennifer R. McDuffie, Deanna Befus, Soheir Adam, Varsha Masilamani, Megan Van Noord ; research associates, Avishek Nagi, Liz Wing.
Connect to full text Available online
View online- Format:
- Book
- Government document
- Author/Creator:
- Goldstein, Karen M., author.
- Coeytaux, Remy R., author.
- Williams, John W., Jr., author.
- Series:
- Evidence-based synthesis program (Series)
- Evidence-based synthesis program
- Language:
- English
- Subjects (All):
- Vasomotor system--Physiology--United States.
- Vasomotor system.
- Menopause--Hormone therapy--United States.
- Menopause.
- Alternative medicine.
- Therapeutics, Physiological.
- Hot Flashes--therapy.
- Vasomotor System--physiology.
- Complementary Therapies.
- Menopause--Hormone therapy.
- United States.
- Medical Subjects:
- Menopause.
- Hot Flashes--therapy.
- Vasomotor System--physiology.
- Complementary Therapies.
- Physical Description:
- 1 online resource (iv, 93 pages) : illustrations (chiefly color).
- Place of Publication:
- Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, July 2016.
- Summary:
- Vasomotor symptoms (VMS), which include hot flashes and night sweats, are the most common symptoms reported during the menopausal transition and are experienced by as many as 80% of women. VMS can lead to increased healthcare encounters for symptom relief and reductions in quality of life. The degree to which VMS is bothersome is determined not only by how frequently it occurs but also by other factors such as duration of VMS, coexisting sleep problems, and the extent to which VMS interferes with daily activities or job-related activities. Hormone therapy (HT) is an effective treatment for reducing VMS, but use of this therapeutic approach must be individualized through weighing benefits with known risks, such as cardiovascular events or uterine and breast cancers. Based on age (> 45 years), currently half of the approximately 360,000 women Veterans who use Veterans Health Administration healthcare are perimenopausal or postmenopausal. Due in part to concerns about possible harms from long-term hormone therapy and in part to uncertain efficacy and safety of pharmacologic treatments, many women with VMS seek nonhormonal, nonpharmacologic treatment options.
- Notes:
- "July 2016."
- Includes bibliographical references (pages 61-68).
- Description based on online resource; title from PDF cover (VA, viewed February 19, 2021).
- OCLC:
- 1004963947
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.